Table 1 The treatment response and prognostic value of IDH mutations in adult AML patients
From: Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
Reference |  | % (Mut/All) | Common co-mutation | CR + CRi (%) | RR | OS | RFS | Prognostic value | Disease |
|---|---|---|---|---|---|---|---|---|---|
[29] | IDH2 | 12.1 (54/446) | – | 72.2 | – | 12y-OS, median not reached | – | Favorable | AML |
[30] | IDH1 | 5.5 (27/493) | – | 72.4 | – | – | – | No value | AML |
[39] | IDH1 R132 | 8 (107/1333) | NPM1+ | 81 | 10y: 55%; | 10y: 34% | 10y: 30% | No value | AML |
[42] | IDH2 R140 | 8 (119/1473) | NPM1+ | 88 | 5y: 28%, 10y: 35% | 5y: 57%, 10y: 46% | – | Favorable | AML |
[42] | IDH2 R172 | 2 (29/1473) | None | 48 | 5y: 70%, 10y: 70% | 5y: 24%, 10y: 9% | – | Advers | AML |
[44] | IDH1 R132 | 16 (34/213) | NPM1+ | 76 | 5y: 64% | 4y: 46% | – | No value | CN-AML |
[44] | IDH2 R172 | 6 (12/205) | None | 58 | 5y: 100% | 4y: 0% | – | Poor | CN-AML |
[45] | IDH1 R132 | 14 (49/358) | NPM1+ | 73 | – | 3y: 29% | – | No value | CN-AML |
[45] | IDH2 R140 | 16 (56/358) | NPM1+ | 70 | – | 3y: 39% | – | No value | CN-AML |
[45] | IDH2 R172 | 4 (13/358) | None | 38 | – | 3y: 0% | – | Poor | CN-AML |
[46] | IDH1 R132 | 7.5 (32/426) | – | 91 | – | Median-OS: 20.9% | – | poor | AML |
[46] | IDH2 R140 | 7.3 (31/426) | – | 74 | – | Median-OS: 35.8% | – | – | AML |
[46] | IDH2 R172 | 2.6 (11/423) | – | 100 | – | Median-OS: 41.1% | – | Favorable | AML |
[47] | IDH2 R172 | 1 (18/1540) | None | – | – | 8y-OS: about 60% | – | Favorable | AML |